




BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

An enforceable international compact for infectious diseases


07 May 2008 | News



An enforceable international compact for infectious diseases

*Prof. Harvey Rubin is a professor of medicine, microbiology and computer science, and the director, University of Pennsylvania Institute for Strategic Threat Analysis and Response.
(rubinh@mail.med.upenn.edu)*

*Prof. C Kameswara Rao is the executive secretary of the Foundation for Biotechnology Awareness and Education (FBAE), Bangalore and a member of the Committees of the US National Academies of Science and the WHO on dual use life science technologies related to global health security.
(chaakaaraav@yahoo.com)*



Human beings have raced with pathogens but always lagged a few steps behind in combating them. In the 21st century, it is an arms race, not between states, but between the global community and naturally occurring pathogens. A very potential new threat emanates from dual use of life science technologies, involving nefariously disseminated pathogens. Endemic, epidemic and pandemic infectious diseases now threaten global health and international security, and this requires global responses to track, detect, prevent and treat infectious diseases.

The reports of the US National Intelligence Council (2000) and of the US Institute of Medicine (2003) brought into focus the threat to global health security from microbial agents. A document of the US Central Intelligence Agency (CIA) (2003)

analyzed "The Darker Bioweapons Future" and concluded that "the effects of engineered biological agents could be worse than any disease known to man". The US National Security Strategy cautions that "public health challenges like pandemics (HIV/AIDS, avian influenza) recognize no borders" (2006). The risks to social order are so great that "traditional public health approaches are inadequate, necessitating new strategies and responses."

The Infectious Diseases Society of America observed that "in a growing and frightening number of cases, the pathogenic bacteria are resistant to many approved drugs, and patients have to be treated with new, investigational compounds or older, toxic alternatives." A report of the Woodrow Wilson School of Public and International Affairs (Princeton University) warns that "new diseases and antibiotic-resistant strains of old ones are on the rise".

Deliberate misuse of emerging technologies

The deliberate spread of infectious diseases misusing otherwise beneficial life science technologies has emerged as an attractive option for bioterrorists which is now a major global security concern. The issue of dual use of beneficial research and technologies has been discussed in depth, by such international Committees and Working Groups as the two Committees of the US National Academies, one on "Biotechnology Research in the Age of Terrorism" (2002-2003) and the other on "Advances in Technology and the Prevention of their Application to Next Generation Biowarfare Threats" (2004-2005), World Health Organization's (WHO) Special Working Group on Life Science Research and Global Health Security, that has been meeting at different places since October 2006, the US National Institutes of Health and WHO's International Round Table on Dual Use Life Sciences Research (February 2007), the Organization for Economic Co-operation and Development's (OECD) High Level Forum on Medicines for Neglected and Emerging Infectious Diseases (June 2007) and the 2nd International forum on Biosecurity (March 2008).

Socio-economic impact of infectious diseases

The predominance of infectious diseases has an undeniable moral significance and highlights our collective failure to give this problem, with implications for the economic well-being of both the developed and developing world, the attention it deserves. The significant role infectious diseases play in the perpetuation of poverty in the developing world is well recognized. They destroy family structures, and limit economic and educational opportunities affecting the economic security of all nations. While the social disintegration that follows an epidemic is known to sections of general public, the consequent economic disruption is far less known. A few weeks after the identification of the Severe Acute Respiratory Syndrome (SARS), the disease had already cost nearly \$30 billion, an amount sufficient to prevent eight million deaths from infectious disease worldwide. A potential H5N1 pandemic costs much more, with economic losses approaching \$600 billion in the US alone, depending on the virulence strain. The spread of pathogenic bacteria that are becoming increasingly resistant to the existing antibiotics imposes a persistent cost in terms of both health and currency.

Lessons from the past

Over the past 25 years, there have been several successful efforts at resolving complex and sometimes overlooked international issues, from the perspectives of both implementation and end-stage achievements. Six NGOs who met in October of 1992 in New York founded the International Campaign to Ban Landmines (ICBL). Five years later, the international "Convention on the Prohibition of the Use, Stockpiling, Production and Transfer or Anti-Personnel Mines and on Their Destruction" came into force and the ICBL was awarded the Nobel Peace Prize "as a model for similar processes in the future". The essential issues surrounding infectious diseases possess similar normative force, which hopefully indicates a similar potential for progress.

The efforts of the Consultative Group on International Agricultural Research (CGIAR) resulted in a massive increase in cereal yield in the second half of the 20th century, averting a global food crisis. CGIAR is an important antecedent combining North/South representation with innovative research and a truly lasting impact in some of the poorest regions in the world.

The magnitude of the threat of infectious diseases similarly necessitates a major global, investigative effort. The lasting positive impacts of international research centers are many, including fostering long-term relationships between scientists, establishing a culture of research responsibility and serving as the nucleus for safe applications of interdisciplinary sciences globally.

The key to any progress against infectious diseases is a structure that brings together diverse interests in a lasting manner. Without such a structure, the commitment to reducing the impact of infectious diseases on our national, economic and personal security will be subject to the political vagaries of the moment, leaving us unprepared for any health crisis.

The daunting realities

- Each year 300 million cases of malaria kill two million people;
- An estimated three percent of the world's population are chronically infected with hepatitis C virus, with about four million newly infected each year, 80 percent of whom will progress to a chronic infection associated with cirrhosis (about 20 percent) and liver cancer (about five percent);
- Of about two billion people infected with hepatitis B virus, some 400 million are chronically infected and one million people die each year from hepatitis B and its complications;
- One third of the world is infected with tuberculosis with 10 million new cases every year accounting for two million deaths;
- Approximately 50 million people worldwide are infected with HIV, which killed 3.9 million in 2005; and
- Despite the attention given to diseases like HIV/AIDS and avian influenza, some outbreaks are still relatively unknown to the general public yet represent a serious burden on global health. Cholera, for example, still causes about 120,000 deaths per year.

International compact for infectious diseases

Considering the general threat scenario of natural and deliberate spread of infectious diseases and the international consensus on preparing to face the threats, Prof. Harvey Rubin has developed, with intellectual inputs from over a score of active microbiologists and pathologists mostly from North America and Europe, the "International Compact for Infectious Diseases", with a four-point strategy for handling threats from infectious diseases:

Compact core mission I: Establish, maintain and monitor a shared international data and knowledge base for infectious diseases, including but not limited to biosurveillance information, relevant pharmaceutical data and suites of services and skills.

Compact core mission II: Establish, maintain and monitor a network of international basic science research centers that will support fundamental investigations into the pathophysiology of certain microbial threats to global health.

Compact core mission III: Expand capabilities for the production of vaccines and therapeutics expressly for emerging and re-emerging infections.

Compact core mission IV: Establish, maintain and monitor international standards for best laboratory and regulatory practices.

IT Architecture

The Information Technology Architecture proposed for the Infectious Disease Compact will seamlessly integrate most of the existing databases, make them user friendly, yet provide the necessary security and add new data as recommended by the wide user community. Though the challenges here are formidable, they are hardly insurmountable. The greatest obstacle is the need for trust between signatory nations and a willingness to share data. There are technical challenges as well. Any attempt to create a common architecture for information systems would require common ontologies. New algorithms and models of disease spread have to be developed and validated. Lastly, the language of the compact has to address the issue of member states, which do not report, or significantly under-report, the incidence of communicable diseases.

Anticipated benefits

The compact is expected to afford the following benefits to signatory nations from both the developed and developing worlds:

- Provide access to cheaper, more highly standardized specific therapeutics and vaccines that are relevant to the signatories;
- Ensure better quality control of vaccines, therapeutics and diagnostics in the developing world, leading to fewer expired or counterfeit agents;

Treaties, conventions and comprehensive compacts

There is no comprehensive program for infectious diseases and the Biological Weapons Convention (BWC) is inadequate.

While international treaties and conventions have some advantages like providing for an international legal basis for enforcement, creating a body of durable "hard law" around an issue and drawing on the power of governments to regulate and license within their jurisdiction, the drawbacks are that ratification is slow and may limit action on urgent issues and the states may perceive enforcement clauses as an unacceptable burden, or even as a threat to their sovereignty.

While compacts have the benefits of being effective governance structures that are quick to set up and provide a framework for action, bring together a broad coalition of partners around a central issue and promote voluntary compliance of laboratories, companies, etc., they suffer from such drawbacks as that enforcement relies on soft power and voluntary compliance, which may prove ineffective during a health crisis.

The answer is a "Comprehensive International Compact for Infectious Diseases", a two-pronged approach with the states as the eligible parties and ratification as the method of participation. Treaty and compact are complementary systems that provide for parallel frameworks for different parties, the overall project will, over time, achieve the benefits of each. Domestic partners who are signatories to the compact can pressure states to comply with the treaty. Several compact-like international agreements exist in such areas as human rights, environment, arms control and disarmament, and trade and finance.

Legitimacy and understanding of the overall system will be promoted through involvement of both the state and non-state actors.

Implementation of the four core missions of the compact will minimize the impact of infectious diseases on global health, social and economic development and international security. The compact drives innovation and progress in four core areas: information and knowledge sharing, basic science, drug and vaccine development and best laboratory and regulatory practices. These missions are interconnected. Without a strong foundation of basic science, the drug and vaccine pipelines dry up. Similarly, in the absence of effective biosurveillance, it becomes difficult to project which strain of an emerging disease represents the most significant threat, which in turn hampers our ability to create countermeasures. Information technology and knowledge sharing will drive new science, which in turn can modify and inform regulatory initiatives. Standardized regulatory regimes enable new drugs and vaccines that will change global epidemiological patterns and these patterns must be reintegrated into a central database, beginning the cycle again.

Addressing the problem as a whole creates powerful incentives for stakeholders to participate. For example, in order to access a central database containing information on current clinical trials, epidemiological data and new compounds and targets, participants would pledge to implement best laboratory and regulatory practices. By bringing together government, the private sector and academia, the compact allows each group to institutionalize their relations with the others. Pharmaceutical companies and public-private development partnerships can find partners to help take promising leads through to development. With the inclusion of post marketing/post distribution clinical trial data in the database, philanthropic organizations and governments will be able to understand the effects their investments are having throughout the world. Academics will acquire additional funding streams for their research as well as input from their colleagues all over the world. Finally, all parties will work together to harmonize regulatory processes across the board, reducing barriers to market entry for much needed therapeutics and ensuring their wider distribution.

International biosurveillance and reporting

- International biosurveillance and reporting faces certain challenges, particularly at the level of sophistication envisioned in the compact, which include:
- Integrating current initiatives into a national health IT strategy and federal architecture to reduce the risk of duplicative efforts;
- Developing and adopting consistent interoperability standards;
- Creating an open architecture that maximizes the use of off-the-shelf tools;

- Creating enough flexibility to bring together disparate underlying IT languages and technologies to provide a common operating picture;
- Generating the ability to accept multiple data formats used by agencies that provide the biosurveillance information;
- Generating the ability to feed information back to the originating agencies providing biosurveillance information in a format each agency can accept;
- Identifying data flows that will evolve during the developmental process;
- Allowing the methods of analysis to evolve and adapt as new data become available or existing data sets are improved; and
- Knowing and evaluating the effectiveness of the current underlying algorithms, methods, and structures for biosurveillance data analysis.

Organization and governance

In order to accommodate the various interested parties and work within the limits of international law, the compact will embrace a two-pronged approach, working with states in the form of a treaty and with other interested parties (NGOs, academic institutions and the private sector) as a softer, pledge-based agreement.

By providing parallel frameworks for different parties, the overall project will achieve the benefits of each. Domestic groups that pledge their membership can apply pressure to their home states, hopefully speeding ratification of the treaty framework. By bringing together both state and non-state actors, the overall aims of the compact will be debated from a variety of different viewpoints, thereby enhancing the legitimacy of the project and promoting a thorough understanding of its goals.